Drug Trial Radar · NCT06383767
A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jun 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
378
Planned (sponsor's estimate)
Start
Jul 11, 2024
Primary completion
Jun 30, 2027
Study completion Jul 31, 2028
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to evaluate the efficacy and safety of ESG401 in patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer.
Conditions
- Metastatic Breast Cancer
Interventions
ESG401Drug
IV infusion on day 1,8, and 15 of each 28 day cycle
Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice)Drug
Eribulin, capecitabine, gemcitabine or vinorelbine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) assessed by IRC per RECIST 1.1Time frame: Up to 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.